93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy
Year: 2021
Type: article
Abstract: Background: In patients with resected, stage II-III NSCLC, the 5-year disease-free survival (DFS) rate with SoC adjuvant chemotherapy is ~40%. Despite advances with immunotherapy (IO) in the metastatic setting, overall survival (OS) rates for patients with recurrence remain low. Detection of minimal residual disease (MRD), as indicated by circulating tumor DNA (ctDNA), may indicate the presence of clinically indiscernible residual tumor following curative-intent therapy and enable earlier therapeutic intervention, thereby improving outcomes in patients at highest risk of recurrence.
Source: Journal of Thoracic Oncology
Institutions: Sarah Cannon, Tennessee Oncology, Centre Hospitalier Universitaire Vaudois, Sungkyunkwan University, National Cancer Center Hospital East, Memorial Sloan Kettering Cancer Center, Duke Medical Center, Institut Gustave Roussy, Cancer Research UK, University College London, AstraZeneca (United Kingdom), AstraZeneca (United States), University College London Hospitals NHS Foundation Trust, The Francis Crick Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,800
Funders: Breast Cancer Research Foundation, LUNGevity Foundation, Bristol-Myers Squibb, Pfizer, AstraZeneca, Celgene, Wellcome Trust, Francis Crick Institute, Cancer Research UK, National Institute for Health and Care Research, University College London, Rosetrees Trust, Ono Pharmaceutical, Genentech, Stand Up To Cancer, Medical Research Council
OpenAlex ID: W3140565772